PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia
NCT00613119 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 108
Last updated 2019-12-16
Summary
This study will use positron emission tomography (PET) imaging to measure a receptor in the brain that is involved in inflammation. Certain neurological disorders, possibly including frontotemporal dementia (FTD), are associated with increased inflammation in the brain. This study may help elucidate the relationship between FTD and inflammation.
Patients with FTD and healthy volunteers who are 35 years of age or older may be eligible for this study. Candidates are screened with a medical history, physical examination, electrocardiogram, and blood and urine tests.
Participants undergo the following procedures:
* Whole body PET scan: PET uses small amounts of a radioactive chemical called a tracer that labels active areas of the brain so the activity can be seen with a special camera. The tracer used in this study is \[11C\]PBR28. Before starting the scan, a catheter (plastic tube) is placed in a vein in the arm to inject the tracer. Pictures are taken for 1 hour. This short scan is done to determine if \[11C\]PBR28 binds to the subject s receptors, since a number of people do not have binding. Subjects who have binding continue with brain PET and MRI scans, described below.
* Brain PET imaging: Before starting the scan, a catheter is placed in a vein in the arm to inject the tracer,\<TAB\> and another catheter is placed in an artery in the wrist to obtain blood samples during the scan. The subject lies on the scanner bed. A special mask is fitted to the head and attached to the bed to help keep the person s head still during the scan so the images will be clear. An 8-minute transmission scan is done just before the tracer is injected to provide measures of the brain that are helpful in calculating information from subsequent scans. After the tracer is injected, pictures are taken for about 2.5 hours, while the subject lies still on the scanner bed.
* Blood and urine tests are done the day of and the day following each PET scan.
* Magnetic resonance imaging (MRI): An MRI scan is done within 1 year (before or after) of the PET scan. This procedure uses a magnetic field and radio waves to produce images of the brain. The subject lies on a table that is moved into the scanner (a tube-like device), wearing earplugs to muffle the noise of the machine during the scanning process. The test takes about 1 hour....
Conditions
- Frontotemporal Lobar Degeneration
- Dementia
Sponsors & Collaborators
-
National Institute of Mental Health (NIMH)
lead NIH
Principal Investigators
-
Robert B Innis, M.D. · National Institute of Mental Health (NIMH)
Eligibility
- Min Age
- 35 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2008-01-31
- Completion
- 2017-07-13
Countries
- United States
Study Locations
More Related Trials
-
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
NCT02649985 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
PET Whole Body Imaging Using a Peripheral Benzodiazepine Receptor Ligand [C-11]PBR28
NCT00407693 ·Status: COMPLETED ·Phase: PHASE1
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
NCT04396873 ·Status: RECRUITING ·Phase: PHASE1
-
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28
NCT00526916 ·Status: COMPLETED ·Phase: PHASE1
-
PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)
NCT00459693 ·Status: TERMINATED ·Phase: NA
-
Traumatic Brain Injury and Risk for Chronic Traumatic Encephalopathy
NCT02003183 ·Status: COMPLETED
-
Imaging Inflammation in Alzheimer's Disease
NCT02831283 ·Status: COMPLETED ·Phase: PHASE2
-
Molecular Neuroimaging of Neuroinflammation in Neurodegenerative Dementias
NCT02945774 ·Status: RECRUITING ·Phase: NA
-
Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
NCT01209156 ·Status: COMPLETED ·Phase: PHASE1
-
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
NCT05456503 ·Status: RECRUITING ·Phase: PHASE3
-
Synaptic Density, Tau and Multiparametric PET-MR in Brain Trauma, Stroke and Mild Cognitive or Behavioral Impairment.
NCT03514524 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel Translocator Protein (TSPO) Radioligand
NCT03958630 ·Status: TERMINATED ·Phase: PHASE1
-
PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)
NCT02062099 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects
NCT02103894 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions
NCT01028209 ·Status: TERMINATED ·Phase: PHASE1
-
Flortaucipir PET Imaging in Subjects With FTD
NCT03040713 ·Status: COMPLETED ·Phase: PHASE1
-
FDDNP Protocol for Visualizing Brain Proteinopathies to Assist in the Diagnosis of Persons With Suspected CTE and AD
NCT04311281 ·Status: WITHDRAWN
-
PET Study of the Nicotinic System in Epilepsy
NCT03268369 ·Status: COMPLETED ·Phase: NA
-
Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
NCT02676843 ·Status: COMPLETED ·Phase: PHASE2
-
18F-PM-PBB3 PET Study in Tauopathy Including Alzheimer's Disease, Other Dementias and Normal Controls
NCT03625128 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)
NCT00329706 ·Status: COMPLETED ·Phase: NA
-
[18F]PI-2620 Phase 3 Histopathological Study
NCT05641688 ·Status: RECRUITING ·Phase: PHASE3
-
Translocator Protein and Inflammation After Traumatic Brain Injury
NCT01547780 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults
NCT03706261 ·Status: COMPLETED ·Phase: PHASE1
-
18F-AV-1451 PET Imaging in TBI
NCT02512029 ·Status: WITHDRAWN ·Phase: PHASE1